2017-11-13T19:42:55-06:00 2016-12-31 346565596 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE SUITE 1700 IRVINE CA 92612 990 2016-01-01 954772979 CALIFORNIA HEART CENTER FOUNDATION CALI 3102488327 8536 WILSHIRE BOULEVARD 3RD FLOOR BEVERLY HILLS CA 90211 JON KOBASHIGAWA MD PRESIDENT 3102488327 2017-11-13 1 KARA ADAMS P00023315 9497942300 192.231.86.239 2017-11-13 17:01:45 PS P EA7D571819A2DDFF3FA87BB29D436B4703CBDB69 A21C8ECFBAEEE1A023FC812FE8CE0E929F59BD7F 2016 2017-02-10 21:41:12Z JON KOBASHIGAWA MD 8536 WILSHIRE BOULEVARD 3RD FLOOR BEVERLY HILLS CA 90211 1830128 0 X WWW.CALHEART.ORG X 2000 CA PROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE. 12 7 0 7 0 0 1784016 1531356 146199 298766 1031 6 0 0 1931246 1830128 0 0 0 0 1686274 1422984 0 0 0 420440 408790 2106714 1831774 -175468 -1646 133728 58893 197995 124806 -64267 -65913 X THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. 0 0 1494424 298766 THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2016: SCIENTIFIC FORUMS AND EDUCATIONAL ACTIVITIES:* "A CASE-BASED GUIDE TO PULMONARY HYPERTENSION CME" (PASADENA, CA): THIS 1-DAY CME PROGRAM TOOK PLACE ON SATURDAY, JANUARY 23RD, 2016 AT THE WESTIN PASADENA. THE PROGRAM, DESIGNED FOR PRIMARY CARE PHYSICIANS, PULMONOLOGISTS, RHEUMATOLOGISTS, CARDIOLOGISTS AND OTHER AFFILIATED STAFF INTERESTED IN THE PREVENTION AND MANAGEMENT OF PULMONARY HYPERTENSION AND PULMONARY ARTERIAL HYPERTENSION DREW 73 PARTICIPANTS FROM ACROSS SOUTHERN CALIFORNIA. NINE EXPERT FACULTY SPOKE ON THE LATEST DIAGNOSTIC AND THERAPEUTIC ADVANCES FOR PATIENTS WITH PH/PAH WITH DIDACTIC LECTURES, A SERIES OF CASE PRESENTATIONS, AND AUDIENCE PARTICIPATION. OVERALL THE PROGRAM WAS VERY WELL RECEIVED. * "CUTTING EDGE OF TRANSPLANTATION (CEOT)", FEBRUARY 25TH - 27TH, 2016 (PHOENIX, ARIZONA): THIS MEETING, PLANNED BY THE AMERICAN SOCIETY OF TRANSPLANTATION, FEATURED A SPECIAL "HEART TRACK" THAT WAS CHAIRED BY DR. JON KOBASHIGAWA AND SPONSORED BY THE CEDARS-SINAI HEART INSTITUTE. FOCUSED ON THE THEME OF "RESOLVING THE ORGAN SHORTAGE", THE HEART TRACK FEATURED 5 DEDICATED SESSIONS OVER THREE DAYS ON ISSUES AND CHALLENGES FACING THE CARDIOTHORACIC COMMUNITY, INCLUDING PENDING POLICY CHANGES TO U.S. HEART ALLOCATION AND INNOVATIONS IN THE MANAGEMENT OF DONOR HEARTS. WITH DR. KOBASHIGAWA'S LEADERSHIP, THE HEART TRACK FEATURED A FACULTY OF LEADING EXPERTS IN THE FIELD AND ATTRACTED THE HIGHEST ATTENDANCE FROM THE CARDIOTHORACIC COMMUNITY SINCE THE INCEPTION OF THE CEOT MEETING. * "A CONSENSUS CONFERENCE ON THE MANAGEMENT OF ANTIBODIES IN HEART TRANSPLANTATION", APRIL 25TH, 2016 (WASHINGTON, DC): THIS INTERNATIONAL CONFERENCE, PLANNED IN COORDINATION WITH THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION, WAS DESIGNED TO PROVIDE A FORUM FOR AN IN-DEPTH DISCUSSION AMONG THE LEADING EXPERTS IN THE FIELD, INCLUDING CLINICIANS, PATHOLOGISTS AND IMMUNOLOGISTS. THE CONFERENCE SERVED AS A FIRST STEP IN DEVELOPING NEEDED GUIDELINES FOR THE ASSESSMENT AND TREATMENT OF PATIENTS WITH CIRCULATING ANTIBODIES BOTH PRE AND POST HEART TRANSPLANTATION, TO IMPROVE OUTCOMES AND MINIMIZE REJECTION COMPLICATIONS. ATTENDED BY 104 PHYSICIANS FROM 16 COUNTRIES AND REPRESENTING 73 TRANSPLANT CENTERS WORLDWIDE, THE CONFERENCE GENERATED A ROBUST DISCUSSION AND HELPED TO IDENTIFY A PATHWAY TO THE DEVELOPMENT OF GUIDELINES. RESULTS OF THE CONFERENCE WERE PRESENTED AT THE ISHLT ANNUAL MEETING AND SCIENTIFIC SESSIONS AND A PUBLICATION OF CONFERENCE RESULTS IS CURRENTLY PENDING.* "SUCCESS WITH FAILURE: AN ADVANCED HEART DISEASE SYMPOSIUM" (CULVER CITY, CA): THIS 1-DAY SYMPOSIUM ON ADVANCED HEART DISEASE TOOK PLACE ON FRIDAY, JUNE 3RD, 2016. TWENTY-ONE FACULTY SPEAKERS COVERED TOPICS RELATED TO THE PREVENTION AND MANAGEMENT OF HEART FAILURE, HEART TRANSPLANT EVALUATION, POST-TRANSPLANT CARE AND SURGICAL OPTIONS IN HEART FAILURE. THE PROGRAM DREW 201 ATTENDEES CONSISTING OF PHYSICIANS, ALLIED HEALTH PROFESSIONALS, INCLUDING NURSE PRACTITIONERS, TRANSPLANT COORDINATORS, PHYSICIAN ASSISTANTS, RNS AND CASE MANAGERS. (MEETING SPONSOR: JON KOBASHIGAWA, MD) * "NEW INSIGHTS INTO THE IMPACT OF DONOR HLA SPECIFIC AND NON-HLA SPECIFIC ANTIBODIES IN SOLID ORGAN GRAFT OUTCOME" (LOS ANGELES, CA): THIS 1-DAY SYMPOSIUM ON ANTIBODIES IN SOLID ORGAN TRANSPLANTATION TOOK PLACE ON FRIDAY, SEPTEMBER 9TH, 2016. TEN FACULTY SPEAKERS COVERED TOPICS RELATED TO THE TESTING, MONITORING AND TREATMENT OF ANTIBODIES IN SOLID ORGAN TRANSPLANTATION. THE PROGRAM DREW 98 ATTENDEES CONSISTING OF CLINICIANS, PATHOLOGISTS, IMMUNOLOGISTS, FELLOWS AND ALLIED HEALTH WHO WORK IN THE AREA OF SOLID ORGAN TRANSPLANTATION. THE PROGRAM WAS EXTREMELY WELL RECEIVED. * "OPTIMAL CARE & NEW THERAPIES IN ADVANCED HEART DISEASE" (COSTA MESA, CA): THIS ONE-DAY SYMPOSIUM ON ADVANCED HEART DISEASE WAS HELD ON OCTOBER 29TH, 2016 AT THE WESTIN SOUTH COAST PLAZA. THE PROGRAM FEATURED PRESENTATIONS ON TOPICS RELATED TO THE DIAGNOSIS AND TREATMENT OF HEART FAILURE, TRANSPLANTATION, MECHANICAL CIRCULATORY SUPPORT AND PULMONARY HYPERTENSION. THE PROGRAM WAS ATTENDED BY 58 PEOPLE, INCLUDING A NUMBER OF COMMUNITY CARDIOLOGISTS IN THE LOCAL AREA.* "NIH INVESTIGATOR MEETING" (NEW ORLEANS) NOVEMBER 11TH, 2016: THIS ONE-DAY MEETING TOOK PLACE IN TANDEM WITH THE AMERICAN HEART ASSOCIATION'S ANNUAL MEETING AND IN COLLABORATION WITH CO-INVESTIGATORS AT MGH AND MT. SINAI. THE MEETING GATHERED 34 POTENTIAL SITE INVESTIGATORS TO DISCUSS PROTOCOL DEVELOPMENT FOR AN NIH GRANT SUBMISSION FOR A PROJECT INVESTIGATING THE EARLY ADDITION OF IL-6 SIGNALING BLOCKADE TO CONVENTIONAL IMMUNOSUPPRESSION IN THE EARLY POST-TRANSPLANT PERIOD TO DIMINISH PRO-INFLAMMATORY, INNATE AND ADAPTIVE B CELL RESPONSES FOLLOWING HEART TRANSPLANTATION.* HEART TRANSPLANT PRECEPTORSHIPS: THROUGHOUT THE YEAR, WE RECEIVE REQUESTS TO PROVIDE EXTENDED OBSERVATIONAL TRAINING OPPORTUNITIES TO PHYSICIANS AND ADVANCE PRACTICE NURSES FROM VARIOUS INSTITUTIONS WITH AN INTEREST IN THE MANAGEMENT OF HEART TRANSPLANT AND MECHANICAL ASSIST DEVICE PATIENTS. IN THE LAST YEAR, WE HOSTED THE FOLLOWING VISITING PHYSICIANS:DR. TOBIA DEUSE, UNIVERSITY OF CALIFORNIA, SAN FRANCISCODR. SHADI DAOUD, HEALTHCARE PARTNERS OF NEVADADR. BINOY JOHN, MIOT INTERNATIONAL HOSPITAL, CHENNAI, INDIAJENNIFER BALLARD-HERNANDEZ, NP, VA MEDICAL CENTER, LONG BEACHDARREL TERRY, CEO, NEWARK BETH ISRAEL MEDICAL CENTERAMY MOITOZA, NP, SCRIPPSJENNIFER NOWACZYK, NP, SCRIPPSRUTH KUO, NP, SCRIPPSJULIAN EIGNER, NP, SCRIPPS* SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF DR. JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS HAVE BEEN OFFERED TO EIGHT STUDENTS FOR THE SUMMER OF 2016. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WILL BE SUBMITTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES:JAMES T. KWAN: UNIVERSITY OF CONNECTICUT (UNDERGRAD)KAYCEE CHING: UC BERKELEY (UNDERGRAD)LAUREN ARAKAWA: CALIFORNIA STATE POLYTECHNIC UNIVERSITY, POMONA (UNDERGRAD)JENNIFER KREMS: AMHERST COLLEGE (UNDERGRAD)KRISTEN YABUNO: UC IRVINE (UNDERGRAD)KEITH T. NISHIHARA: UC BERKELEY (UNDERGRAD)MICHAEL HASHIMOTO: UCLA (UNDERGRAD)FRANK KEVIN LIOU: DREXEL UNIVERSITY (1ST YEAR MED STUDENT)OLIVIA DING: TULANE UNIVERSITY (1ST YEAR MED STUDENT)CLINICAL RESEARCH:THIS SECTION WILL BE FORMATTED BY TITLE; PRINCIPAL INVESTIGATOR (PI); STATUS; SPONSOR.A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (CEP-41750) IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NONISCHEMIC ETIOLOGY; DAVID CHANG, MD; ENROLLING; TEVA PHARMACEUTICALSA MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL BPS-314D-MR ADDED-ON TO TREPROSTINIL, INHALED (TYVASO) IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION; ANTOINE HAGE, MD; ENROLLING; LUNG BIOTECHNOLOGY, INC. 1494424 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 20 0 1 0 0 0 0 0 0 0 0 0 0 0 X 12 7 1 0 0 0 1 1 1 1 1 0 0 0 1 1 1 0 0 0 1 0 CA X DEBBIE BOTTEN 3104238473 15821 VENTURA BLVD STE 520 ENCINO CA 91436 JON KOBASHIGAWA MD PRESIDENT 2.00 0.00 X X 0 0 0 KEENAN BEHRLE CHAIRPERSON 2.00 0.00 X X 0 0 0 JAMES HAMILTON SECRETARY 2.00 0.00 X X 0 0 0 THOMAS D GORDON CFO 1.00 65.00 X X 0 629294 157990 MICHELE HAMILTON MD DIRECTOR 2.00 0.00 X 0 0 0 RICHARD B JACOBS DIRECTOR 1.00 61.00 X 0 1218884 303262 JOSEPH O LAMPE DIRECTOR 2.00 0.00 X 0 0 0 EDUARDO MARBAN MD DIRECTOR 1.00 60.00 X 0 2320711 203405 LAURENCE MARTON MD DIRECTOR 2.00 0.00 X 0 0 0 ARTHUR J OCHOA DIRECTOR 1.00 65.00 X 0 1001700 63438 WILLIAM OUCHI PHD DIRECTOR 2.00 0.00 X 0 0 0 EDWARD PRUNCHUNAS DIRECTOR 1.00 65.00 X 0 1541844 361892 ERIC N MARTON FORMER PRESIDENT 30.00 30.00 X 0 154565 3756 CHRISTINE SUMBI VICE PRESIDENT 40.00 0.00 X 0 177050 21775 PHYLLIS KATZ EXECUTIVE ASSISTANT 40.00 0.00 X 0 108256 27796 0 7152304 1143314 0 0 1 0 0 1531356 1531356 EDUCATIONAL PROGRAMS 611430 273312 273312 CULTURAL PROGRAMS 611710 25454 25454 298766 6 6 1830128 298766 0 6 286041 286041 932910 932910 52056 52056 69295 69295 82682 82682 4065 4065 54896 38427 16469 7920 7128 792 34278 34278 8044 8044 212298 201683 10615 2849 2849 MEALS AND ENTERTAINMENT 69881 46448 23433 DUES & SUBSCRIPTIONS 6833 6833 MOVING/STORAGE 3944 3944 TELEPHONE 1302 1302 2480 2480 1831774 1494424 337350 0 47646 48209 486 6886 107678 103880 6647 3798 78949 133728 58893 180995 124806 17000 0 197995 124806 X -64267 -65913 -64267 -65913 133728 58893 -1646 0 X 0 0 0 X 1445229 1357431 1514534 1784016 1531356 7632566 1445229 1357431 1514534 1784016 1531356 7632566 7632566 12225 8138 5075 1031 6 26475 7659041 615840 0.99650 0.99390 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 70594 66796 3798 37084 37084 0 3798 0 1 0 0 0 0 0 0 0 THOMAS D GORDON CFO 0 312770 0 187947 0 128577 0 131249 0 26741 0 787284 0 0 RICHARD B JACOBS DIRECTOR 0 649091 0 353238 0 216555 0 286927 0 16335 0 1522146 0 0 EDUARDO MARBAN MD DIRECTOR 0 1470656 0 323081 0 526974 0 168550 0 34855 0 2524116 0 0 ARTHUR J OCHOA DIRECTOR 0 574330 0 284655 0 142715 0 29189 0 34249 0 1065138 0 0 EDWARD PRUNCHUNAS DIRECTOR 0 794056 0 377165 0 370623 0 335871 0 26021 0 1903736 0 0 ERIC N MARTON FORMER PRESIDENT 0 106232 0 40000 0 8333 0 0 0 3756 0 158321 0 0 CHRISTINE SUMBI VICE PRESIDENT 0 157459 0 19254 0 337 0 12574 0 9201 0 198825 0 0 PART I, LINE 3 THE PRESIDENT IS COMPENSATED BY A RELATED ORGANIZATION. PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, SECTION B LINE 15B. PART I, LINE 4B THE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. THE FOLLOWING OFFICERS AND DIRECTORS RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2016. THOMAS D. GORDON 120,883 RICHARD B. JACOBS 164,337 EDUARDO MARBAN, MD 297,145 ERIC N. MARTON 8,276 ARTHUR J. OCHOA 124,109 EDWARD PRUNCHUNAS 299,972 FORM 990, PART III, LINE 4A (CONTINUED) A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECT DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM); JIGNESH PATEL, MD, PHD; ENROLLMENT COMPLETE; PFIZER A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE; ANTOINE HAGE, MD; STUDY START-UP; UNITED THERAPEUTICS A PHASE 3 MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALN-TTRSC IN PATIENTS WITH TRANSTHYRETIN (TTR) MEDIATED FAMILIAL AMYLOIDOTIC CARDIOMYOPATHY (FAC); JIGNESH PATEL, MD, PHD; ENROLLMENT COMPLETE; ALNYLAM PHARMACEUTICALS A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE 20MG OR 80MG IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM); JIGNESH PATEL, MD, PHD; STUDY START-UP; PFIZER A PHASE 3, PLACEBO CONTROLLED DOUBLE-BLIND, RANDOMIZED, CLINICAL STUDY TO DETERMINE EFFICACY, SAFETY AND TOLERABILITY OF PULSED, INHALED NITRIC OXIDE(INO) VERSUS PLACEBO IN SYMPTOMATIC SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH); ANTOINE HAGE, MD; STUDY START-UP; BELLEROPHON PULSE TECHNOLOGIES LLC A PHASE III, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF DALCETRAPIB ON CARDIOVASCULAR (CV) RISK IN A GENETICALLY DEFINED POPULATION WITH A RECENT ACUTE CORONARY SYNDROME (ACS); BABAK AZARBAL, MD; STUDY START-UP; DALCOR PHARMA UK LTD A PHASE III, INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL WORSENING STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION RECEIVING BACKGROUND ORAL MONOTHERAPY; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS A PROSPECTIVE, RANDOMIZED, CONTROLLED, UNBLINDED, MULTI-CENTER CLINICAL TRIAL TO EVALUATE THE HEARTWARE VENTRICULAR ASSIST DEVICE SYSTEM FOR DESTINATION THERAPY OF ADVANCED HEART FAILURE; JAIME MORIGUCHI, MD; ENROLLING; HEARTWARE, INC. A PROSPECTIVE, SINGLE ARM, MULTI-CENTER CLINICAL STUDY IN COLLABORATION WITH THE INTERAGENCY REGISTRY FOR MECHANICALLY ASSISTED CIRCULATORY SUPPORT (INTERMACS) TO EVALUATE THE THORACOTOMY IMPLANT TECHNIQUE OF THE HEARTWARE HVAD SYSTEM IN PATIENTS WITH ADVANCED HEART FAILURE; FRANCISCO ARABIA, MD; ENROLLING; HEARTWARE, INC. A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION; ANTOINE HAGE, MD; STUDY START-UP; REATA PHARMACEUTICALS, INC. ADVANCED HEART DISEASE BIOBANK; ROBIN SHAW, MD; ENROLLING; CSMC ADVANCED HEART DISEASE REGISTRY; JON KOBASHIGAWA, MD; ENROLLING; CSMC AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE; ANTOINE HAGE, MD; STUDY START-UP; UNITED THERAPEUTICS AN OPEN-LABEL EXTENSION STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION - A LONG-TERM FOLLOW-UP TO PROTOCOL TDE-PH-310; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS BIOMARKERS OF PRIMARY GRAFT DYSFUNCTION AFTER CARDIAC TRANSPLANTATION; JON KOBASHIGAWA, MD; STUDY START-UP; COLUMBIA UNIVERSITY CARDIOMEMS HF SYSTEM POST APPROVAL STUDY; LAWRENCE CZER, MD; ENROLLING; ST. JUDE MEDICAL CELL-FREE DNA AND ANTIBODY-MEDIATED REJECTION IN A COHORT OF SENSITIZED HEART TRANSPLANT PATIENTS; JON KOBASHIGAWA, MD; ENROLLING; CSMS/CAREDX, INC. DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF MICROARRAYS IN HEART TRANSPLANTATION, A MULTICENTER STUDY; JON KOBASHIGAWA, MD; ENROLLING, UNIVERSITY OF ALBERTA EXTERNAL FACTORS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS; A SINGLE CENTER SURVEY STUDY; JON KOBASHIGAWA, MD; ENROLLING; CSMC HDL LEVELS AND CARDIAC ALLOGRAFT VASCULOPATHY (CAV); JON KOBASHIGAWA, MD; ENROLLING; CSMC HOME ECG MONITORING TO DETECT ALLOGRAFT REJECTION FOLLOWING HEART TRANSPLANTATION; JON KOBASHIGAWA, MD; ENROLLMENT COMPLETE; UCSF/NIH INTERAGENCY REGISTRY FOR MECHANICALLY ASSISTED CIRCULATORY SUPPORT; FRANCISCO ARABIA, MD; ENROLLING; UAB/NIH INTERNATIONAL TRIAL TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE PORTABLE ORGAN CARE SYSTEM (OCS) HEART FOR PRESERVING AND ASSESSING EXPANDED CRITERIA DONOR HEARTS FOR TRANSPLANTATION; FARDAD ESMAILIAN, MD; ENROLLING; TRANSMEDICS, INC. OBSERVATIONAL REVIEW OF CLINICAL OUTCOMES IN HEART FAILURE PATIENTS UNDERGOING BARIATRIC SURGERY; MICHELE HAMILTON, MD; ENROLLING; CSMC OUTCOMES ALLOMAP REGISTRY (OAR) STUDY; JON KOBASHIGAWA, MD; ENROLLING; CAREDX, INC. PULMONARY HYPERTENSION POST-LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION; JAIME MORIGUCHI, MD; ENROLLING; ACTELION PHARMACEUTICALS REGISTRY EVALUATION OF VITAL INFORMATION FOR VADS IN AMBULATORY LIFE; MICHELLE KITTLESON, MD, PHD; ENROLLMENT COMPLETE; UNIVERSITY OF MICHIGAN RISK STRATIFICATION PRIOR TO TANDEM ORTHOTOPIC HEART AND STEM CELL TRANSPLANT IN PATIENTS WITH SYSTEMIC AMYLOIDOSIS; JON KOBASHIGAWA, MD; ENROLLING; CSMC TANDEMHEART EXPERIENCES AND METHODS; DANNY RAMZY, MD, PHD; STUDY START-UP; CARDIACASSIST, INC. THE DE-NOVO USE OF ECULIZUMAB ALONGSIDE CONVENTIONAL THERAPY IN PRESENSITIZED PATIENTS RECEIVING CARDIAC TRANSPLANTATION: AN OPEN-LABEL, INVESTIGATOR-INITIATED PILOT TRIAL; JIGNESH PATEL, MD, PHD; ENROLLING, ALEXION PHARMACEUTICALS THE MEDICAL ARM OF MECHANICAL CIRCULATORY SUPPORT (MEDAMACS) STUDY; MICHELLE KITTLESON, MD, PHD; ENROLLMENT COMPLETE; UAB/NIH US-BASED, OBSERVATIONAL, DRUG REGISTRY OF OPSUMIT (MACITENTAN) NEW USERS IN CLINICAL PRACTICE; ANTOINE HAGE, MD; ENROLLING; ACTELION PHARMACEUTICALS FORM 990, PART IV, LINE 12 THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/16 AND 6/30/17 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/16. FORM 990, PART VI, SECTION A, LINE 2 LAURENCE MARTON, MD, DIRECTOR AND ERIC MARTON, FORMER PRESIDENT HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION A, LINE 6 CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7A CEDARS-SINAI MEDICAL CENTER AS THE SOLE CORPORATE MEMBER, CAN ELECT BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7B RESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) SUBJECT TO SECTION 5.08, APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; AND (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15B THE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT ON BEHALF OF THE BOARD WITH RESPECT TO SUCH ISSUES, AND OTHER GOVERNANCE ISSUES AS REQUESTED BY THE BOARD OF DIRECTORS, THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, THE CHAIR OF THE BOARD OF DIRECTORS, OR THE CEO, ALL SUBJECT TO THE COMMITTEE'S ONGOING REPORTING OBLIGATION TO THE BOARD OF DIRECTORS OR THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. SPECIFICALLY, THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. THE MEMBERS OF THE COMMITTEE ARE APPOINTED ANNUALLY BY THE CHAIR OF THE MEDICAL CENTER'S BOARD OF DIRECTORS. APPOINTMENTS ARE FOR A ONE YEAR TERM. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY INCLUDE MEMBERS OF THE MEDICAL CENTER'S MANAGEMENT TEAM OR ANY OTHER PERSON WHOSE PRESENCE THE COMMITTEE BELIEVES TO BE DESIRABLE OR APPROPRIATE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT AND ANY OTHER ADVISORS THEY DEEM NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. THE COMMITTEE MEETS AS FREQUENTLY AS THE COMMITTEE DEEMS NECESSARY AND WILL MAINTAIN WRITTEN MINUTES OF ITS MEETING. THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND VICE-PRESIDENT ARE DETERMINED BY THE CHIEF FINANCIAL OFFICER OF THE ORGANIZATION WITH ASSISTANCE FROM HR WHICH PROVIDES AN INDEPENDENT REVIEW OF COMPARABLES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, ITS CONFLICT OF INTEREST POLICY AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST. CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 951644600 HEALTHCARE CA 501(C)(3) LINE 3 N/A 0 CEDARS-SINAI MEDICAL CARE FOUNDATION 200 N ROBERTSON BOULEVARD 101 BEVERLY HILLS CA 90211 954457756 PROVISION OF MEDICAL CARE, TEACHING AND RESEARCH CA 501(C)(3) LINE 12A, I CEDARS-SINAI MEDICAL CENTER 1 KERLAN-JOBE ORTHOPAEDIC FOUNDATION 6801 PARK TERRACE LOS ANGELES CA 90045 954707606 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC MEDICINE CA 501(C)(3) LINE 7 CEDARS-SINAI MEDICAL CARE FOUNDATION 1 SANTA MONICA ORTHOPAEDIC & SPORTS MED RESEARCH FDN 2020 SANTA MONICA BLVD 4TH FLR SANTA MONICA CA 90404 954789926 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC AND NEUROLOGIC CONDITIONS CA 501(C)(3) PF CEDARS-SINAI MEDICAL CARE FOUNDATION 1 CFHS HOLDINGS INC 4650 LINCOLN BLVD MARINA DEL REY CA 90292 201645949 HEALTHCARE CA 501(C)(3) LINE 3 CEDARS-SINAI MEDICAL CENTER 1 ENDOSCOPY CENTER OF SANTA MONICA LLC 12400 WILSHIRE BLVD STE 100 LOS ANGELES CA 90025 113652210 ENDOSCOPIES AND RELATED PROCEDURES CA N/A ISS ASC HOLDINGS LLC 27271 LAS RAMBLAS STE 350 MISSION VIEJO CA 92691 471890805 INVESTMENT IN HEALTHCARE SERVICES CA N/A DEL REY SURGERY INVESTORS LLC 11150 SANTA MONICA BLVD STE 700 LOS ANGELES CA 90025 364756208 INVESTMENT IN AMBULATORY SURGERY CENTER DE N/A DEL REY SURGERY CENTER LLC 27271 LAS RAMBLAS STE 350 MISSION VIEJO CA 92691 462305372 OPERATOR OF AMBULATORY SURGERY CENTER CA N/A CEDARS-SINAI BH ASC LLC 200 N ROBERTSON BLVD 101 BEVERLY HILLS CA 90211 812266744 HOLDING COMPANY CA N/A CS-BH ASC HOLDINGS LLC 200 N ROBERTSON BLVD 101 BEVERLY HILLS CA 90211 812246488 HOLDING COMPANY CA N/A INTERNATIONAL SPINE & ORTHOPEDIC INSTITUTE LLC 8500 W 110TH ST OVERLAND PARK KS 66210 263738893 SPINE AND ORTHOPEDIC INSTITUTE DE N/A OPTIMATRIX HEALTH SOLUTIONS INC 6500 WILSHIRE BLVD 9TH FLR LOS ANGELES CA 90048 954522779 INFORMATION SYSTEMS CA N/A C 1 CENTINELA FREEMAN HOLDINGS INC 4650 LINCOLN BLVD MARINA DEL REY CA 90292 593811890 MEDICAL OFFICE BUILDING AND GROUND LEASE LESSOR CA N/A C 1 OTOHARMONICS CORPORATION 411 SW 6TH AVE PORTLAND OR 97204 461119421 HEALTHCARE PRODUCT DEVELOPMENT DE N/A C 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0